Broadly neutralizing antibody VRC34-combo.1 in complex with HIV fusion peptide (residue 512-519)

Geospatial HIV-1 subtype C gp120 sequence diversity and its predicted impact on broadly neutralizing antibody sensitivity

Abstract Evolving diversity in globally circulating HIV-1 subty

Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates

Abstract Novel therapeutic and preventive strategies are needed

Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression

A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings

Background: HIV Vaccine Trials Network 703/HIV Prevention Trials Network 081 is a phas

Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART

Introduction Monthly intravenous infusion of broadly neutralizing monoclonal antibodies may be an

A Potent, Neutralizing Human Monoclonal Antibody against a Unique Epitope Overlapping the CD4-Binding Site of HIV-1 gp120 That Is Broadly Conserved across North American and African Virus Isolates

A human monoclonal antibody (HuMAb), 5145A, against HIV-1 gp120 was isolated from an asymptomatic, s